RegStem develops and repurposes drugs for regenerative medicine, licensing them to pharmaceutical companies after clinical trials. Established in 2017, this ground-breaking biotechnology and biopharmaceutical company is situated in Paris Biotech Santé, a life science incubator located in central Paris. The company's primary focus is on researching, developing, and licensing innovative molecules with potential for human therapies. RegStem's ultimate goal is to introduce and license new pro-regenerative drugs to the pharmaceutical industry following successful clinical trials. Their last investment of €71.43K came in the form of a grant from EASME - EU Executive Agency for SMEs on 01 November 2018.
RegStem is at the forefront of innovation in the field of regenerative medicine, addressing critical unmet needs within the biotechnology industry. Through their strategic focus on repurposing and developing drugs, they have positioned themselves as a key player in advancing potential therapies for regenerative medicine. Their location within the Paris Biotech Santé provides an advantageous environment for collaboration and growth.
The recent €71.43K grant investment from EASME underscores external confidence in RegStem's vision and capabilities. This injection of capital will likely propel their ongoing research and development efforts, as well as contribute to the advancement of their clinical trials. With a clear commitment to bridging the gap between drug development and commercialization, RegStem presents an intriguing opportunity for investment within the rapidly evolving biotechnology landscape.
Taxonomy:
Biopharmaceutical, Regenerative Medicine, Drug Repurposing, Clinical Trials, Pharmaceutical Licensing, Paris Biotech Santé, Innovation, Rare Diseases, Muscle Diseases, Blood Diseases, Healthcare Research, Therapeutic Molecules, Early Stage, Life Science Incubator
